Currency In USD
| Previous Close | 8.34 |
| Open | 7.99 |
| Day High | 8.19 |
| Day Low | 7.16 |
| 52-Week High | 95.6 |
| 52-Week Low | 6.69 |
| Volume | 31,818.42 |
| Average Volume | 16,362 |
| Market Cap | 1.81M |
| PE | -1.63 |
| EPS | -4.4 |
| Moving Average 50 Days | 8.95 |
| Moving Average 200 Days | 20.34 |
| Change | -1.18 |
Beyond Air to Participate in the 38th Annual Roth Conference in March
GlobeNewswire Inc.
Mar 11, 2026 11:00 AM GMT
GARDEN CITY, N.Y., March 11, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve th
Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.
GlobeNewswire Inc.
Mar 10, 2026 11:30 AM GMT
GARDEN CITY, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve t
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections
GlobeNewswire Inc.
Feb 20, 2026 1:00 PM GMT
GARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve th